Are Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? – Making Safe, Durable & Effective Universal Cell Therapies a Reality

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T ‘Cemacabtagene Ansegedleucel/ALLO-501’ in Relapsed/Refractory Large B-Cell Lymphoma.